Aim: To study the reduction in macular oedema in Central Retinal Vein Occlusion cases following Intravitreal injection of Bevacizumab using Spectral Domain Optical Coherence Tomography. Methods: 50 patients diagnosed with Central Retinal Vein Occlusion with macular oedema of more than 300 microns on Spectral Domain Optical Coherence Tomography ( SD-OCT) ,who attended to Out patient Department of Government Regional Eye Hospital (GREH) between January 2020 to June 2020 were administered Intravitreal Injection of Bevacizumab (Avastin) 1.25mg in 0.05ml. Re-injections were given if SD-OCT showed persistence of macular oedema. In follow up visits, patients were evaluated with SD-OCT and Central macular thickness (CMT) was measured every month till 6 months from the date of first injection. Results: Out of 50 cases included in the study, there was reduction in macular oedema in 45 (90%) cases and 5% had persistence of macular edema. Conclusion: Intravitreal Bevacizumab is a safe and effective modality of treatment for reducing macular edema due to Central Retinal Vein Occlusion as per our study.
Investigation of Retinal Morphology Alterations Using Spectral Domain Optical Coherence Tomography in a Mouse Model of Retinal Branch and Central Retinal Vein Occlusion
